Features of the course of non-alcoholic fatty liver disease in HIV-infected individuals
PDF (Русский)

Keywords

non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, human immunodeficiency virus, metabolic syndrome, antiretroviral therapy

How to Cite

Akhmedov, V. A., Mamedova, N. F., Verbanov, A. V., Gaus, O. V., & Gaus, O. V. (2020). Features of the course of non-alcoholic fatty liver disease in HIV-infected individuals. Herald of Pancreatic Club, 47(2), 66-71. https://doi.org/10.33149/vkp.2020.02.07

Abstract views: 20
PDF Downloads: 11

Abstract

This article reflects the course of non-alcoholic fatty liver disease (NAFLD) in HIV-infected individuals. It is noted that long-term antiretroviral therapy and the use of D-drugs can explain the high prevalence of steatosis in this category of patients. The results of experimental studies that demonstrate the direct effect of HIV on liver steatosis by infection of stellate liver cells, stimulation of abnormal expression of SREBP-1 and PPARγ are considered. The role of HIV-mediated microbial translocation as one of the triggers for the development of non-alcoholic steatohepatitis (NASH), which contributes to chronic inflammation due to an increase in the permeability of the intestinal barrier to bacterial products and endotoxins, is noted. Data are presented confirming the high prevalence of the abnormal distribution of fat and visceral obesity (components of lipodystrophy syndrome) in a cohort of HIV-infected individuals. There was a high prevalence of steatosis and steatohepatitis in HIV-infected patients with lipodystrophy as compared with HIV-infected patients without lipodystrophy. Data showing the high prevalence of NASH in HIV-infected individuals are presented. A high rate of progression of NAFLD in a cohort of HIV-infected individuals was observed, regardless of the presence/absence of a combined viral infection (chronic hepatitis C). It has been established that the classic risk factors for NAFLD (high body mass index, dyslipidemia, metabolic syndrome) can contribute to the rapid progression of the disease in people living with HIV, compared with representatives of the general population.

https://doi.org/10.33149/vkp.2020.02.07
PDF (Русский)

References

1. Achhra A. C., Mocroft A., Reiss P. et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016. Vol. 17, No 4. Р. 255–268.
2. Akhtar M. A., Mathieson K., Arey B. et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur. J. Gastroenterol. Hepatol. 2008. Vol. 20, No 12. Р. 1194–1204.
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002. Vol. 346, No 16. Р. 1221–1231.
4. Apostolova N., Blas-Garcia A., Esplugues J. V. Mitochondrial interference by anti-HIV drugs: mechanisms beyond pol-gamma inhibition. Trends Pharmacol. Sci. 2011. Vol. 32, No 12. Р. 715–725.
5. Borges V. F., Diniz A. L., Cotrim H. P. et al. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J. Clin. Ultrasound. 2013. Vol. 41, No 1. Р. 18–25.
6. Brown T. T., Xu X., John M. et al. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the multicenter AIDS cohort study. AIDS Res. Ther. 2009. No 6. Р. 1–8.
7. Byrne C. D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015. Vol. 62, Suppl. 1. S. 47–64.
8. Bzowej N. H. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr. Opin. Organ Transplant. 2018. Vol. 23, No 2. Р. 169–174.
9. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology. 2012. Vol. 142, No 7. Р. 1592–1609.
10. Diehl A. M., Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 2017. Vol. 377, No 21. Р. 2063–2072.
11. Fung J., Lee C. K., Chan M. et al. High prevalence of non-alcoholic fatty liver disease in the Chinese — results from the Hong Kong liver health census. Liver Int. 2015. Vol. 35, No 2. Р. 542–549.
12. Guaraldi G., Lonardo A., Ballestri S. et al. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch. Med. Res. 2011. Vol. 42, No 8. Р. 690–697.
13. Guaraldi G., Squillace N., Stentarelli C. et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin. Infect. Dis. 2008. Vol. 47, No 2. Р. 250–257.
14. Hadigan C., Liebau J., Andersen R. et al. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J. Acquir Immune Defic. Syndr. 2007. Vol. 46, No 3. Р. 312–317.
15. Hsue P. Y. Mechanisms of cardiovascular disease in the setting of HIV infection. Can. J. Cardiol. 2019. Vol. 35, No 3. Р. 238–248.
16. Ingiliz P., Valantin M. A., Duvivier C. et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009. Vol. 49, No 2. Р. 436–442.
17. Joy T., Keogh H. M., Hadigan C. et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J. Acquir. Immune Defic. Syndr. 2008. Vol. 47, No 2. Р. 174–184.
18. Kalia H. S., Gaglio P. J. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin. Liver Dis. 2016. Vol. 20, No 2. Р. 215–224.
19. Kardashian A., Ma Y., Scherzer R. et al. Sex differences in the association of HIV infection with hepatic steatosis. AIDS. 2017. Vol. 31, No 3. Р. 365–373.
20. Karlas T., Petroff D., Sasso M. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 2017. Vol. 66, No 5. Р. 1022–1030.
21. Lee S. S., Park S. H., Kim H. J. et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J. Hepatol. 2010. Vol. 52, No 4. Р. 579–585.
22. Lemoine M., Barbu V., Girard P. M. et al. Altered hepatic expression of SREBP-1 and PPARγ is associated with liver injury in insulinresistant lipodystrophic HIV-infected patients. AIDS. 2006. Vol. 20, No 3. Р. 387–395.
23. Li Vecchi V., Soresi M., Giannitrapani L. et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int. J. Infect. Dis. 2012. Vol. 16, No 5. P. e397–402.
24. Lombardi R., Sambatakou H., Mariolis I. et al. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig. Liver Dis. 2016. Vol. 48, No 12. Р. 1471–1477.
25. Lozupone C. A., Rhodes M. E., Neff C. P. et al. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes. 2014. Vol. 5, No 4. Р. 562–570.
26. Lui G., Wong V. W., Wong G. L., et al. Liver fibrosis and fatty liver in Asian HIV-infected patients. Aliment. Pharmacol. Ther. 2016. Vol. 44, No 4. Р. 411–421.
27. Macias J., Gonzalez J., Tural C. et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS. 2014. Vol. 28, No 9. Р. 1279–1287.
28. Macias J., Mancebo M., Merino D. et al. Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease. Clin. Infect. Dis. 2017. Vol. 65, No 6. Р. 1012–1019.
29. Macias J., Real L. M., Rivero-Juarez A. et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med. 2016. Vol. 17, No 10. Р. 766–773.
30. Mohammed S. S., Aghdassi E., Salit I. E. et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J. Acquir. Immune Defic. Syndr. 2007. Vol. 45, No 4. Р. 432–438.
31. Morse C. G., McLaughlin M., Matthews L. et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin. Infect. Dis. 2015. Vol. 60, No 10. Р. 1569–1578.
32. Nguyen A., Calmy A., Delhumeau C. et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011. Vol. 25, No 12. Р. 1481–1487.
33. Nishijima T., Gatanaga H., Shimbo T. et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One. 2014. Vol. 9, No 1. P. e87596.
34. Onyekwere C. A., Ogbera A. O., Balogun B. O. Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann. Hepatol. 2011. Vol. 10, No 2. Р. 119–124.
35. Park B. J., Kim Y. J., Kim D. H. et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J. Gastroenterol. Hepatol. 2008. Vol. 23, No 6. Р. 900–907.
36. Park S. H., Kim P. N., Kim K. W. et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006. Vol. 239, No 1. Р. 105–112.
37. Pembroke T., Deschenes M., Lebouche B. et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J. Hepatol. 2017. Vol. 67, No 4. Р. 801–808.
38. Price J. C., Dodge J. L., Ma Y. et al. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults. AIDS. 2017. Vol. 31, No 15. Р. 2119–2125.
39. Price J. C., Ma Y., Scherzer R. et al. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology. 2017. Vol. 65, No 3. Р. 853–863.
40. Price J. C., Seaberg E. C., Latanich R. et al. Risk factors for fatty liver in the multicenter AIDS cohort study. Am. J. Gastroenterol. 2014. Vol. 109, No 5. Р. 695–704.
41. Sasso M., Beaugrand M., de Ledinghen V. et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 2010. Vol. 36, No 11. Р. 1825–1835.
42. Sayiner M., Koenig A., Henry L. et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin. Liver Dis. 2016. Vol. 20, No 2. Р. 205–214.
43. Sfikas G. B. C., Tassios K., Kaitanidis K. et al. Non-alcoholic fatty liver disease in HIV-infected patients without viral hepatitis what can we do about their cardiovascular risk? Hel. J. Atherosclerosis. 2016. Vol. 7, No 1. Р. 5–12.
44. Shlay J. C., Visnegarwala F., Bartsch G. et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J. Acquir. Immune Defic. Syndr. 2005. Vol. 38, No 2. Р. 147–155.
45. Sterling R. K., Smith P. G., Brunt E. M. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J. Clin. Gastroenterol. 2013. Vol. 47, No 2. Р. 182–187.
46. Sulyok M., Makara M., Rupnik Z. et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study. Eur. J. Gastroenterol. Hepatol. 2015. Vol. 27, No 6. Р. 679–685.
47. van der Poorten D., Milner K. L., Hui J. et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008. Vol. 48, No 2. Р. 449–457.
48. van Werven J. R., Marsman H. A., Nederveen A. J. et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1HMR spectroscopy. Radiology. 2010. Vol. 256, No 1. Р. 159–168.
49. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011. Vol. 34, No 3. Р. 274–285.
50. Vodkin I., Valasek M. A., Bettencourt R. et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment. Pharmacol. Ther. 2015. Vol. 41, No 4. Р. 368–378.
51. Webb M., Yeshua H., Zelber-Sagi S. et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am. J. Roentgenol. 2009. Vol. 192, No 4. Р. 909–914.
52. Zilberman-Schapira G., Zmora N., Itav S. et al. The gut microbiome in human immunodeficiency virus infection. BMC Med. 2016. Vol. 14, No 1. Р. 83.